Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.

Breast cancer is increasingly recognized to represent a heterogeneous group of diseases that vary in their treatment response, recurrence risk, and overall prognosis.1 Since Perou et al2 first described 4 distinct subtypes of breast cancer on the basis of gene expression profiles, there has been growing emphasis on the molecular characteristics of breast cancer and personalized medicine. In the neoadjuvant chemotherapy setting, imaging plays a critical role in noninvasively assessing the response of the intact primary tumor to targeted systemic therapies.